Regulator Warns of Fake P-2 Pills.

Identified as batch number T34197R and containing 0.75 mg of levonorgestrel, the falsified product falsely claims to have been manufactured by Gedeon Richter. Authorities caution that the pills could pose serious health risks to anyone who uses them.

Dr Ahmed Mohamed, Chief Executive Officer of the Board, explained the potential dangers clearly. “This batch may contain incorrect amounts of the active ingredient, no active ingredient at all, harmful contaminants, or undeclared substances,” he said. As a result, the product might simply fail to provide the intended protection, leaving users exposed to unintended consequences.

Officials have highlighted several clear differences that distinguish the fake packs from genuine ones. These include irregularities in batch printing, typographical errors on the patient information leaflet, and a different method of sealing the carton. Authentic packs from the manufacturer use a hot-melt closure, while the counterfeit versions do not. The orange colouring on the branding is also noticeably more intense, and the logo revealed after scratching the authentication panel appears in a different font.

Healthcare professionals have been urged to carefully check their stocks before dispensing any Postinor-2 tablets and to immediately quarantine any products matching the suspect batch. Hospitals, distributors, pharmacists and members of the public are encouraged to report any encounters with batch T34197R without delay. The Board further advises that all pharmaceutical products should be obtained exclusively from licensed manufacturers, importers, distributors and retailers.

Members of the public can flag suspected counterfeit medicines through the Board’s online reporting portal, the USSD code *271#, the mPvERS mobile application or other official contact channels. The warning forms part of wider efforts to protect consumers from the growing threat of falsified medical products and to safeguard public health across the country.